Media-OutReach Newswire The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Politics & Law Singaporean PM’s visit will be crucial to comprehensive strategic partnership: ambassador